Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials
ConclusionSGLT2 inhibitors were associated with a reduced risk of atrial arrhythmias in patients with T2DM. Our results support the use of SGLT2 inhibitors in T2DM with high cardiovascular risk populations. We also recommend the long-term use of SGLT2 inhibitors to achieve further benefits.Graphical abstract
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
More News: Arrhythmia | Atrial Fibrillation | Cardiac Arrhythmia | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | SGLT2 Inhibitors | Sodium | Ventricular Tachycardia